KalVista Pharmaceuticals (NASDAQ:KALV) Major Shareholder Venrock Healthcare Capital Par Sells 39,986 Shares of Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) major shareholder Venrock Healthcare Capital Par sold 39,986 shares of the company’s stock in a transaction that occurred on Thursday, March 26th. The stock was sold at an average price of $18.28, for a total transaction of $730,944.08. Following the transaction, the insider owned 5,089,354 shares of the company’s stock, valued at approximately $93,033,391.12. This represents a 0.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Venrock Healthcare Capital Par also recently made the following trade(s):

• On Wednesday, March 25th, Venrock Healthcare Capital Par sold 174,645 shares of KalVista Pharmaceuticals stock. The shares were sold at an average price of $16.95, for a total transaction of $2,960,232.75.

KalVista Pharmaceuticals Stock Performance

Shares of KalVista Pharmaceuticals stock opened at $19.33 on Friday. The company’s 50 day moving average price is $16.04 and its two-hundred day moving average price is $14.46. The firm has a market capitalization of $990.08 million, a P/E ratio of -4.89 and a beta of -0.35. KalVista Pharmaceuticals, Inc. has a fifty-two week low of $9.23 and a fifty-two week high of $19.95. The company has a debt-to-equity ratio of 8.18, a current ratio of 7.22 and a quick ratio of 7.21.

Analyst Ratings Changes

A number of brokerages recently weighed in on KALV. Citizens Jmp reduced their price objective on KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating on the stock in a research report on Thursday. Weiss Ratings reiterated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research report on Thursday, January 22nd. Wall Street Zen raised KalVista Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday. Stifel Nicolaus boosted their price target on KalVista Pharmaceuticals from $39.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday. Finally, HC Wainwright upped their price target on shares of KalVista Pharmaceuticals from $27.00 to $37.00 and gave the company a “buy” rating in a research report on Friday, January 9th. Seven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $32.60.

KalVista Pharmaceuticals News Summary

Here are the key news stories impacting KalVista Pharmaceuticals this week:

• Positive Sentiment: Unusual bullish options flow: traders bought 5,072 call options (≈569% above the average of 758), suggesting speculative or hedged bullish positioning that can amplify near-term upside interest in the shares.
• Positive Sentiment: Stifel Nicolaus raised its price target to $42 and reiterated a “buy” rating — a large upside vs. the current level that often attracts renewed investor attention and buying. Stifel price target raise
• Positive Sentiment: Needham & Company increased its target to $36 and kept a “buy” rating, reinforcing analyst conviction from multiple firms. Needham target raise
• Positive Sentiment: EKTERLY commercial launch showing strong initial revenue: KalVista reported $49.1M in EKTERLY revenue during an eight-month transition period — a material commercial proof point that supports revenue growth expectations. EKTERLY revenue report
• Positive Sentiment: Stock hit a new 52-week high after analyst upgrades and increased coverage, a technical signal that can attract momentum buyers. 52-week high / analyst upgrade
• Neutral Sentiment: Recent earnings materials (Q1 2025 call summary and transcript) have been published — useful for revisiting guidance and management commentary but the market reaction depends on details and forward guidance. Q1 2025 earnings call summary
• Negative Sentiment: Citizens Jmp trimmed its price target slightly from $29 to $28 (still a “market outperform”), a modest downtick in one analyst’s view that could temper upside expectations if other firms follow. Citizens Jmp target change

Institutional Investors Weigh In On KalVista Pharmaceuticals

A number of institutional investors have recently made changes to their positions in KALV. BNP Paribas Financial Markets increased its stake in shares of KalVista Pharmaceuticals by 47.0% in the second quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock valued at $46,000 after buying an additional 1,292 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of KalVista Pharmaceuticals in the third quarter worth approximately $55,000. Wolverine Asset Management LLC acquired a new position in shares of KalVista Pharmaceuticals in the third quarter worth approximately $57,000. KLP Kapitalforvaltning AS bought a new stake in KalVista Pharmaceuticals in the third quarter valued at approximately $63,000. Finally, Truvestments Capital LLC boosted its holdings in KalVista Pharmaceuticals by 253.8% in the fourth quarter. Truvestments Capital LLC now owns 4,684 shares of the specialty pharmaceutical company’s stock valued at $76,000 after acquiring an additional 3,360 shares during the last quarter.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.